Contrasting Rosetta Genomics (ROSG) & Idera Pharmaceuticals (NASDAQ:IDRA)

Rosetta Genomics (NASDAQ: ROSG) and Idera Pharmaceuticals (NASDAQ:IDRA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.

Risk & Volatility

Rosetta Genomics has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500. Comparatively, Idera Pharmaceuticals has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500.

Earnings & Valuation

This table compares Rosetta Genomics and Idera Pharmaceuticals’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Rosetta Genomics $9.23 million 0.39 -$16.23 million ($9.31) -0.06
Idera Pharmaceuticals $16.20 million 28.15 -$38.38 million ($0.34) -6.88

Rosetta Genomics has higher earnings, but lower revenue than Idera Pharmaceuticals. Idera Pharmaceuticals is trading at a lower price-to-earnings ratio than Rosetta Genomics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Rosetta Genomics and Idera Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rosetta Genomics 0 1 0 0 2.00
Idera Pharmaceuticals 0 0 5 0 3.00

Idera Pharmaceuticals has a consensus price target of $5.40, indicating a potential upside of 130.77%. Given Idera Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Idera Pharmaceuticals is more favorable than Rosetta Genomics.


This table compares Rosetta Genomics and Idera Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Rosetta Genomics -239.57% -290.92% -157.81%
Idera Pharmaceuticals -313.78% -60.80% -55.07%

Insider & Institutional Ownership

7.5% of Rosetta Genomics shares are owned by institutional investors. Comparatively, 24.1% of Idera Pharmaceuticals shares are owned by institutional investors. 12.4% of Idera Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.


Idera Pharmaceuticals beats Rosetta Genomics on 11 of the 14 factors compared between the two stocks.

About Rosetta Genomics

Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH). It is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY and RosettaGX Reveal. Its therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. It focuses on developing diagnostic assay, RosettaGX Reveal V2. It is also focusing on developing Bladder cancer risk stratification. Its PersonalizeDx is focused on the detection of genomic changes through FISH technology, which helps to detect cancer.

About Idera Pharmaceuticals

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company’s drug candidates include IMO-8400, IMO-2125 and IMO-9200. The Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. It is developing its 3GA technology to turn off the mRNA associated with disease causing genes.

Receive News & Ratings for Rosetta Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics and related companies with's FREE daily email newsletter.

Leave a Reply